Perspectives on Ensifentrine and Its Therapeutic Potential in the Treatment of COPD: Evidence to Date.

Authors:
Faruqi MA; Khan MMKS; Mannino DM.

Journal:
Int J Chron Obstruct Pulmon Dis

Publication Year: 2024

DOI:
10.2147/COPD.S385811

PMCID:
PMC10771716

PMID:
38188891

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Int J Chron Obstruct Pulmon Dis

Abbreviation: Int J Chron Obstruct Pulmon Dis

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pulmonary Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Abhd2, a Candidate Gene Regulating Airway Remodeling in COPD via TGF-β.
Lv MY; Jin LL; Sang XQ and 4 more (2024) - Transparency Score: 3/6
Acute Exacerbation and Longitudinal Lung Function Change of Preserved Ratio Impaired Spirometry.
Yoon SM; Jin KN; Lee HJ and 5 more (2024) - Transparency Score: 3/6
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Due to Carbapenem-Resistant <i>Klebsiel…
Ouyang P; Zhou Z; Pan C and 5 more (2024) - Transparency Score: 2/6
Addressing Barriers to Chronic Obstructive Pulmonary Disease (COPD) Care: Three Innovative Evidence…
Siu DCH; Gafni-Lachter L. (2024) - Transparency Score: 2/6
ApoA1, ApoB, ApoA1/B for Pathogenic Prediction of Chronic Obstructive Pulmonary Disease Complicated…
Meng J; Yang W; Chen Z and 4 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure Drs. Faruqi and Khan report no conflicts of interest. Dr. Mannino is a consultant to GlaxoSmithKline, AstraZeneca, Regeneron, Genentech and The COPD Foundation, receives royalties from Up to Date, and is an expert witness on behalf of people suing the tobacco and vaping industries."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025